Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-EB-FAPI in Metastatic Tumors
NCT05400967Phase 1Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2022
- Primary completion
- Jan 2025
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of 177Lu-DOTA-EB-FAPI in tumor, sponsored by Peking Union Medical College Hospital. Primary endpoints: Safety of therapy at 1 year and Therapeutic effect at 1 year. Started Jan 2022; status: recruiting.
02
Drugs
177Lu-DOTA-EB-FAPI
03
Conditions
tumor
Beyond the preview
Go deeper on NCT05400967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05400967.